Eli Lilly

Showing 15 posts of 203 posts found.


Lilly’s Olumiant impresses in twin Phase 3 atopic dermatitis trials

February 5, 2019
Manufacturing and Production, Research and Development Eli Lilly, Olumiant, atopic dermatitis, pharma

Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). …

EMA rejects Lilly’s Lartruvo in soft tissue cancer following trial failure

January 24, 2019
Sales and Marketing Cancer, EMA, Eli Lilly, Lartruvo, pharma

Eli Lilly has been dealt a blow as the European Medicines Agency announced its recommendation for soft tissue cancer patients …


Lilly’s Lartruvo/chemo combo surprises with Phase 3 failure in soft tissue carcinoma

January 21, 2019
Research and Development, Sales and Marketing Cancer, Eli Lilly, carcinoma, chemotherapy, pharma, trial failure

Eli Lilly has reluctantly pulled back the curtain on new Phase 3 data for its platelet-derived growth factor receptor alpha …

Eli Lilly’s Verzenios scores NICE recommendation for advanced breast cancer

January 17, 2019
Sales and Marketing Cancer, Eli Lilly, NICE, Verzenios, breast cancer, pharma

Breast cancer patients in England and Wales now have access to another treatment option, as NICE announces its recommendation of …


Eli Lilly to buy Loxo Oncology in deal worth $8 billion

January 7, 2019
Manufacturing and Production Cancer, Eli Lilly, Loxo Oncology, gene therapy, personalised medicine

US firm Eli Lilly & Co today announced a definitive agreement for the acquisition of Connecticut-based company Loxo Oncology in …


Top Ten most popular articles on Pharmafile.com this week!

December 21, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Eisai, Eli Lilly, Novartis, Teva, Tilray, brexit, celltrion, pharma, top 10

Deals dominated this week as GSK and Pfizer announced that they would combine their consumer healthcare units in a collaboration …

Eli Lilly’s Taltz shows superiority over AbbVie’s Humira

December 18, 2018
Manufacturing and Production Eli Lilly, Humira, Taltz, arthritis, immune system

A study has found that Eli Lilly’s Taltz (ixekizumab) met the primary, and all secondary endpoints, in patients with active …


Eli Lilly’s Emgality cleared for treatment of migraine in Europe

November 20, 2018
Manufacturing and Production, Sales and Marketing EU, Eli Lilly, Emgality, Europe, migraine, pharma

Eli Lilly’s Emgality (galcanezumab) has secured approval from the European Commission for the prophylaxis of migraine in adult patients who …


Lilly’s Trulicity reduces major cardiovascular events in “ambitious” trial of type 2 diabetes

November 7, 2018
Research and Development Eli Lilly, Trulicity, cardiovascular events, pharma, type 2 diabetes

Eli Lilly has revealed new data on Trulicity (dulaglutide), showing that glucagon-like peptide-1 (GLP-1) receptor agonist achieved its primary endpoint …


Pfizer & Lilly’s non-opioid drug reduces pain in osteoarthritis

October 24, 2018
Research and Development Eli Lilly, Pfizer, osteoarthritis, pharma

Pfizer and Eli Lilly have announced data revealing that their nerve growth factor (NGF) inhibitor tanezumab met all three of …

GSK named third best UK workplace

October 22, 2018
Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work

British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …


NICE rejects Elil Lilly’s Verzenio for breast cancer in draft guidance

October 19, 2018
Medical Communications, Sales and Marketing Eli Lilly, NICE, UK, Verzenios, breast cancer, pharma

Eli Lilly and patients with breast cancer patients in the UK have been dealt a blow as NICE confirmed that …

Lilly’s Verzenio gets first-line EU approval for HER2- advanced breast cancer

October 3, 2018
Research and Development, Sales and Marketing Cancer, Eli Lilly, Verzenio, breast cancer, pharma

The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged. The therapy …

NICE recommends Eli Lilly’s psoriatic arthritis drug

August 9, 2018
Research and Development, Sales and Marketing Eli Lilly, England, NICE, Wales, psoriatic arthritis

Eli Lilly have announced that the monoclonal antibody ixekizumab, has been recommended by NICE for use as a treatment option …


Eli Lilly’s dulaglutide doses show blood control and weight benefits at Phase 2

June 25, 2018
Research and Development, Sales and Marketing Eli Lilly, Trulicity, diabetes, pharma

Eli Lilly has announced new data on its once-weekly, injectable glucagon-like peptide Trulicity (dulaglutide 1.5mg) and investigational 3.0 and 4.5mg …

Latest content